Molecular profiling in the treatment of colorectal cancer: Focus on regorafenib

Yiyi Yan, Axel Grothey

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.

Original languageEnglish (US)
Pages (from-to)2949-2957
Number of pages9
JournalOncoTargets and Therapy
StatePublished - Oct 15 2015


  • Metastatic colon cancer
  • Molecular profiling
  • Regorafenib
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Molecular profiling in the treatment of colorectal cancer: Focus on regorafenib'. Together they form a unique fingerprint.

Cite this